-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Recently, China Resources Sanjiu mentioned in its institutional survey, "The price of OTC products is relatively market-oriented, and the company has certain pricing pow.
The company's OTC products have two types of price increas.
One is the price of core varieties due to years of listi.
There is no change, but the cost has risen a lot, so the price of this type of products will be gradually increased slightly, mainly to cover the impact of the rising cost, and at the same time to realize the brand value, the process of price increase will fully consider the patient's acceptan.
The second is the growing varieties that are being cultivat.
With the improvement of product brand power, there is a process of gradual price increase; at the same time, the company continues to upgrade product experience, improve technology and packaging design, and accordingly will increase the price according.
” In this regard, the industry People pointed out that OTC (over-the-counter drugs) may be affected by rising costs and product upgrades, and may welcome price increases again, but the overall magnitude is not expected to be lar.
It is worth mentioning that OTC (over-the-counter) price changes are already comm.
In recent years, affected by factors such as rising labor costs, rising environmental protection costs, the promotion of the two-invoice system, and consistency evaluation, the operating costs of enterprises have continued to rise, and there have been constant news about the price increase of OTC produc.
For example, as early as 2018, a number of listed companies including China Resources Sanjiu and Yunnan Baiyao introduced in their disclosed investor relations activity records that the company's related products had undergone price increases of varying degre.
At that time, China Resources Sanjiu mentioned that it has made a small price increase for products such as Sanjiu Weitai, Ganmaoling, and Qiang Loquat Dew in recent yea.
The company also stated that the key to competition in the OTC market lies in brandi.
The company will continue to focus on brand buildi.
The company will gradually sort out its price strategy, and will make decisions on products based on its own brand positioning, consumer acceptance, and competition in related categori.
price adjustme.
Yunnan Baiyao has raised prices on Band-Aids, hemorrhoid creams and aeroso.
The company said that the price adjustment is mainly considered for channel providers, especially retail termina.
The OTC competition is fierce, and the profit margin in the channel is very sma.
In order to mobilize the enthusiasm of the channel dealers and make up for the profit defect of the product channel, the price adjustment was ma.
In addition, the ex-factory price has also been adjusted, but the overall adjustment is sma.
Since March 1, 2018, Foci Pharma has raised the prices of more than 100 products in various dosage forms such as concentrated pills, honeydew pills, water pills, oral liquids, gels, granules, and table.
The ex-factory prices of the above products The average increase is 16%, and the retail price will also be adjusted according.
In addition, pharmaceutical companies such as Bikang .
, L.
, Pien Tze Huang, Dong'e Ejiao, Jiangzhong Group, Sanjin Guilin, and Ma Yinglong have also reported some price increases for some OTC produc.
The main reasons behind this are factors such as the continuous increase in the price of raw materials of Chinese medicinal materials and the improvement of the quality of medicinal materials under strict supervisi.
It is understood that these OTC varieties that have raised prices include large varieties and small varieti.
For example, a number of commonly used low-priced drugs such as digoxin tablets and erythromycin ointment have adjusted their pric.
The industry believes that small price increases for OTC due to factors such as rising costs are inevitable, but when pharmaceutical companies raise prices, they also need to comprehensively consider market competition and consumer acceptan.
From the perspective of product price increases, chain pharmacies may even benefit more than manufacture.
From the perspective of medical reform policies in recent years, with the promotion of a number of policies such as the normalization of centralized procurement and medical insurance negotiations, "reducing drug prices" is still the main tone of the pharmaceutical indust.
The company's OTC products have two types of price increas.
One is the price of core varieties due to years of listi.
There is no change, but the cost has risen a lot, so the price of this type of products will be gradually increased slightly, mainly to cover the impact of the rising cost, and at the same time to realize the brand value, the process of price increase will fully consider the patient's acceptan.
The second is the growing varieties that are being cultivat.
With the improvement of product brand power, there is a process of gradual price increase; at the same time, the company continues to upgrade product experience, improve technology and packaging design, and accordingly will increase the price according.
” In this regard, the industry People pointed out that OTC (over-the-counter drugs) may be affected by rising costs and product upgrades, and may welcome price increases again, but the overall magnitude is not expected to be lar.
It is worth mentioning that OTC (over-the-counter) price changes are already comm.
In recent years, affected by factors such as rising labor costs, rising environmental protection costs, the promotion of the two-invoice system, and consistency evaluation, the operating costs of enterprises have continued to rise, and there have been constant news about the price increase of OTC produc.
For example, as early as 2018, a number of listed companies including China Resources Sanjiu and Yunnan Baiyao introduced in their disclosed investor relations activity records that the company's related products had undergone price increases of varying degre.
At that time, China Resources Sanjiu mentioned that it has made a small price increase for products such as Sanjiu Weitai, Ganmaoling, and Qiang Loquat Dew in recent yea.
The company also stated that the key to competition in the OTC market lies in brandi.
The company will continue to focus on brand buildi.
The company will gradually sort out its price strategy, and will make decisions on products based on its own brand positioning, consumer acceptance, and competition in related categori.
price adjustme.
Yunnan Baiyao has raised prices on Band-Aids, hemorrhoid creams and aeroso.
The company said that the price adjustment is mainly considered for channel providers, especially retail termina.
The OTC competition is fierce, and the profit margin in the channel is very sma.
In order to mobilize the enthusiasm of the channel dealers and make up for the profit defect of the product channel, the price adjustment was ma.
In addition, the ex-factory price has also been adjusted, but the overall adjustment is sma.
Since March 1, 2018, Foci Pharma has raised the prices of more than 100 products in various dosage forms such as concentrated pills, honeydew pills, water pills, oral liquids, gels, granules, and table.
The ex-factory prices of the above products The average increase is 16%, and the retail price will also be adjusted according.
In addition, pharmaceutical companies such as Bikang .
, L.
, Pien Tze Huang, Dong'e Ejiao, Jiangzhong Group, Sanjin Guilin, and Ma Yinglong have also reported some price increases for some OTC produc.
The main reasons behind this are factors such as the continuous increase in the price of raw materials of Chinese medicinal materials and the improvement of the quality of medicinal materials under strict supervisi.
It is understood that these OTC varieties that have raised prices include large varieties and small varieti.
For example, a number of commonly used low-priced drugs such as digoxin tablets and erythromycin ointment have adjusted their pric.
The industry believes that small price increases for OTC due to factors such as rising costs are inevitable, but when pharmaceutical companies raise prices, they also need to comprehensively consider market competition and consumer acceptan.
From the perspective of product price increases, chain pharmacies may even benefit more than manufacture.
From the perspective of medical reform policies in recent years, with the promotion of a number of policies such as the normalization of centralized procurement and medical insurance negotiations, "reducing drug prices" is still the main tone of the pharmaceutical indust.
